TEZCAT BIOSCIENCES, INC.
NEW HAVEN, CT
What changed
NIH R44 · $0.2M · A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
May 2025Grant renewalMay 13, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 18 out of 100, unchanged since the last recompute.
Little recent filing activity, or the events on file have decayed.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Grant-only
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Peer position
10,731 pre-ticker oncology companies at Grant-only
Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.
Compare seatsA ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Grant
R44 · $206k · non-dilutive
Jul 15, 2020TEZCAT BIOSCIENCES, INC. · PI RAMIREZ, CRAIG PATRICK · NCI · award ends Jul 31, 2026 · A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
NIH RePORTER · NIH RePORTER 11260526 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources